CMV-encoded TNF receptor and viral dissemination
CMV 编码的 TNF 受体和病毒传播
基本信息
- 批准号:7640222
- 负责人:
- 金额:$ 8.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-19 至 2011-05-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAffectAntiviral TherapyAttenuatedCMV glycoprotein BCell LineCellsCellular ImmunityChemotactic FactorsClinicalCo-ImmunoprecipitationsCoculture TechniquesCohort StudiesCytomegalovirusCytomegalovirus InfectionsCytomegalovirus VaccinesDNA VaccinesDataDiseaseFetusGenesGeneticGenetic PolymorphismGenotypeHelper-Inducer T-LymphocyteHerpesviridaeHumanImmuneImmune responseImmunocompromised HostImmunologic SurveillanceIn VitroInfantInfectionInstitute of Medicine (U.S.)LMP1LaboratoriesLymphocyteMediator of activation proteinMolecularMorbidity - disease rateMothersNewborn InfantOpen Reading FramesOutcomePathogenesisPharmaceutical PreparationsPlayPopulationPregnancyProductionProteinsReceptor GeneRegulatory T-LymphocyteRiskRoleSamplingSignal TransductionSignaling ProteinSystemT-Cell ProliferationT-LymphocyteTNF Receptor-Associated FactorsTestingToxic effectTransfectionTumor Necrosis Factor ReceptorTumor Necrosis Factor-alphaTumor Necrosis FactorsViralVirusWorkchemokinecongenital cytomegaloviruscongenital infectioncytokinehigh voltage electron microscopyinsightinterestmacrophage-derived chemokinemortalitypathogenpreventpublic health relevancereceptorresearch studyresponsevaccine candidatevaccine developmentvirus host interaction
项目摘要
DESCRIPTION (provided by applicant): Cytomegalovirus (CMV) infection is widespread and is usually asymptomatic. The virus establishes lifelong latency in the host and becomes a major pathogen when transmitted during pregnancy from mother to fetus, and in immunocompromised hosts. The risk of CMV disease is determined by multiple host and viral factors, but it is unknown whether specific CMV strains are more likely to reactivate and disseminate than others. Currently available antiviral therapies have decreased morbidity and mortality of CMV disease but are limited by toxicities and by variable efficacy in established disease. CMV vaccine is currently not available to prevent congenital infection or disease in immunocompromised hosts. We have been studying human CMV genes located in the UL/b' region of the virus (UL131-UL150). These genes are deleted in laboratory adapted strains but exist in all clinical isolates; therefore, thought to play a pathogenesis role in the host. Some of these genes encode for cytokines and chemokines that may interfere with host immune responses. We sequenced UL144 (TNF1 receptor gene), UL146 and UL147 (1 chemokine genes) from multiple human samples, and defined their polymorphisms. We also showed in two cohort studies that polymorphisms in UL144 correlate with outcome of congenital CMV infection. Recent studies show that the ectodomain of UL144 interacts with the B and T cell lymphocyte attenuator and inhibits T cell proliferation in vitro. UL144 also activates NF-:B, resulting in enhanced expression of the chemokine CCL22, a chemoattractant for Th2 lymphocytes. These studies suggest that UL144 plays a role in interference with host immune surveillance possibly via effects on Th1/Th2 responses, which may help CMV to disseminate. Our hypothesis is that UL144 has a role in allowing CMV to disseminate in the host. Certain UL144 genotypes may elicit less effective host cell mediated immunity than others because of differences in signaling and in activation of Th1 responses, diverting the immune response towards a Th2 response. We propose the following specific aims: 1) to determine some aspects of the molecular mechanisms by which UL144 activates NF-:B. We will determine which domain of UL144 is important in signaling, and identify proteins that interact with UL144. 2) To determine the effects of UL144 on Th1/Th2 responses in vitro. Using co-culture system the effects of UL144 genotypes on Th1/Th2 lymphocyte responses and cytokine production will be determined. PUBLIC HEALTH RELEVANCE: We hope to provide new perspectives and better understanding of the mechanisms by which UL144 activates NF- :B. We will also provide insight into the differences between UL144 genotypes in their signaling and their ability to affect Th1/Th2 responses. Understanding the role of UL144 in allowing viral dissemination and immune evasion, may open a new strategy for drug and vaccine development.
描述(申请人提供):巨细胞病毒(CMV)感染广泛,通常是无症状的。这种病毒在宿主中建立了终生潜伏期,并在怀孕期间从母亲传播给胎儿时成为主要病原体,并在免疫受损的宿主中传播。CMV病的风险由多种宿主和病毒因素决定,但目前尚不清楚特定的CMV毒株是否比其他毒株更有可能重新激活和传播。目前可用的抗病毒疗法已经降低了CMV病的发病率和死亡率,但受到毒性和对已确定疾病的不同疗效的限制。巨细胞病毒疫苗目前还不能用于预防免疫受损宿主的先天性感染或疾病。我们一直在研究位于病毒UL/b‘区(UL131-UL150)的人CMV基因。这些基因在实验室适应菌株中缺失,但在所有临床分离株中都存在;因此,被认为在宿主中起致病作用。其中一些基因编码细胞因子和趋化因子,可能会干扰宿主的免疫反应。我们从多个人类样本中测定了UL144(TNF1受体基因)、UL146和UL147(1个趋化因子基因)的序列,并确定了它们的多态性。在两项队列研究中,我们还发现UL144基因的多态与先天性巨细胞病毒感染的结局相关。最近的研究表明,UL144的胞外区与B和T淋巴细胞衰减剂相互作用,并在体外抑制T细胞的增殖。UL144还激活了核因子-B,导致趋化因子CCL22的表达增强,CCL22是Th2淋巴细胞的趋化诱导剂。这些研究表明,UL144可能通过影响Th1/Th2应答而干扰宿主的免疫监视,这可能有助于CMV的传播。我们的假设是UL144在允许CMV在宿主中传播方面起到了作用。由于信号和Th1反应激活的不同,某些UL144基因可能比其他类型诱导的宿主细胞介导的免疫效果更差,从而将免疫反应转向Th2反应。我们提出了以下具体目标:1)确定UL144激活核因子-的分子机制的某些方面:B.我们将确定UL144的哪个结构域在信号转导中起重要作用,并确定与UL144相互作用的蛋白质。2)体外检测UL144对Th1/Th2应答的影响。采用共培养系统,检测UL144基因分型对Th1/Th2淋巴细胞反应和细胞因子产生的影响。公共卫生相关性:我们希望提供新的视角,更好地理解UL144激活核因子-B的机制。我们还将深入了解UL144不同基因型在信号传递方面的差异,以及它们影响Th1/Th2反应的能力。了解UL144在允许病毒传播和免疫逃避中的作用,可能会开启药物和疫苗开发的新战略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ravit Boger其他文献
Ravit Boger的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ravit Boger', 18)}}的其他基金
Autophagy activation – a novel strategy for inhibition of human cytomegalovirus
自噬激活——抑制人类巨细胞病毒的新策略
- 批准号:
10442936 - 财政年份:2022
- 资助金额:
$ 8.2万 - 项目类别:
Autophagy activation – a novel strategy for inhibition of human cytomegalovirus
自噬激活——抑制人类巨细胞病毒的新策略
- 批准号:
10615151 - 财政年份:2022
- 资助金额:
$ 8.2万 - 项目类别:
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors
用于鉴定人类巨细胞病毒抑制剂的高通量筛选
- 批准号:
8870334 - 财政年份:2014
- 资助金额:
$ 8.2万 - 项目类别:
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors
用于鉴定人类巨细胞病毒抑制剂的高通量筛选
- 批准号:
9056570 - 财政年份:2014
- 资助金额:
$ 8.2万 - 项目类别:
High Throughput Screening for Identification of Human Cytomegalovirus Inhibitors
用于鉴定人类巨细胞病毒抑制剂的高通量筛选
- 批准号:
8756332 - 财政年份:2014
- 资助金额:
$ 8.2万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8415971 - 财政年份:2011
- 资助金额:
$ 8.2万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8227951 - 财政年份:2011
- 资助金额:
$ 8.2万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8082274 - 财政年份:2011
- 资助金额:
$ 8.2万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8795657 - 财政年份:2011
- 资助金额:
$ 8.2万 - 项目类别:
Novel Artemisinin Derivatives for Cytomegalovirus Therapy
用于巨细胞病毒治疗的新型青蒿素衍生物
- 批准号:
8603834 - 财政年份:2011
- 资助金额:
$ 8.2万 - 项目类别:
相似海外基金
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 8.2万 - 项目类别:
Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 8.2万 - 项目类别:
Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 8.2万 - 项目类别:
Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 8.2万 - 项目类别:
Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 8.2万 - 项目类别:
Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 8.2万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 8.2万 - 项目类别:
Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
- 批准号:
2301846 - 财政年份:2023
- 资助金额:
$ 8.2万 - 项目类别:
Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 8.2万 - 项目类别:
Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
- 批准号:
23K16076 - 财政年份:2023
- 资助金额:
$ 8.2万 - 项目类别:
Grant-in-Aid for Early-Career Scientists